Clinical trial: Oral drug keeps cancer treatment on track for patients who develop persistently low platelet counts

Дата публикации: 20-07-2026 20:40:01

In a phase 2 clinical trial, Mass General Brigham Cancer Institute researchers found that the oral drug avatrombopag was safe and effective in managing persistent chemotherapy-induced thrombocytopenia (CIT) in more than half of patients with gastrointestinal cancers, offering a potential new option for managing a common and challenging complication of cancer treatment. Their work is published in the Journal of Clinical Oncology.

Основное содержимое страницы с новостью.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer	5	7	02-07-2026
2	EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin	0	5	19-06-2026
3	Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors	0	7	25-06-2026
4	Neoadjuvant Serplulimab with S-1 Plus Oxaliplatin Followed by Adjuvant Serplulimab Significantly Improves EFS in PD-L1-positive, Resectable Gastric or GEJ Adenocarcinoma	5	7	30-06-2026
5	Российские ученые создали препарат для снижения побочных эффектов при лечении рака	5	7	05-07-2026
6	В РФ готовят к выпуску первый отечественный препарат против онкозаболевания крови	0	0	25-04-2025
7	New treatment helps achieve a healthier BMI in people with weight dysregulation after brain tumors	5	7	09-07-2026
8	Decentralized clinical trials expand access for rural and underserved patients	7	8	20-07-2026
9	Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2 -Positive Breast Cancer	0	7	25-06-2026
10	حقنة جديدة تبعث الأمل.. علاج واعد يقضي على أورام السرطان	7	8	01-06-2026

Классификация: . Схожих патентов: 0. Схожих новостей: 10. Тональность: 5. Информативность: 7. Источник: medicalxpress.com.